The report provides an epidemiological update on cholera outbreaks in Haiti as of January 17, 2023. Since the first confirmed cases in October 2022, Haiti has reported 24,232 suspected cases, including 1,742 confirmed cases and 483 deaths. The most affected areas are in the Ouest Department, particu...larly Port-au-Prince. Children aged 1 to 4 years are the most affected group. The ongoing humanitarian crisis, security issues, and limited access to healthcare have worsened the outbreak, hindering epidemiological surveillance and case reporting. The PAHO/WHO is working with Haitian authorities to respond to the outbreak and mitigate its spread.
more
Le document fournit des lignes directrices sur la gestion des diarrhées aiguës, mettant en avant des solutions de réhydratation orale (SRO) améliorées avec une osmolarité réduite et la supplémentation en zinc. Il souligne leur efficacité pour réduire la durée et la gravité des épisodes ...diarrhéiques et prévenir de futurs cas. Destiné aux familles, aux communautés et aux professionnels de santé, il vise à intégrer ces pratiques dans les soins de routine à domicile et dans les centres de santé.
more
Le document fournit des directives essentielles pour prévenir et gérer les maladies diarrhéiques aiguës, en particulier dans les situations d'urgence complexes comme les conflits, les catastrophes naturelles ou les crises sanitaires. Il met en avant l'importance de l'accès à l'eau potable, de ...l'assainissement, de l'hygiène personnelle et de la prise en charge rapide des malades grâce à des solutions de réhydratation orale (SRO). Le texte insiste également sur la nécessité de la coordination entre les acteurs locaux et internationaux pour une réponse efficace et durable.
more
Malaria in children presents significant clinical challenges, with variations in presentation based on the malaria parasite involved and the child's underlying health conditions. The World Health Organization reports high incidence rates, particularly in sub-Saharan Africa, and emphasizes the import...ance of effective treatment strategies. First-line treatment often involves Artemether-Lumefantrine (ALu), while severe malaria requires careful management and the use of intravenous Quinine. Management protocols emphasize early diagnosis and the monitoring of severe complications to reduce mortality.
more
Le mémoire porte sur la conception et la mise en œuvre d’une campagne de communication pour promouvoir la chimio-prévention du paludisme saisonnier (CPS) chez les enfants de 3 à 59 mois au Cameroun, une stratégie recommandée par l’OMS dans les zones de forte transmission saisonnière. L’...auteure part du constat que, malgré l’introduction de la CPS dans certaines régions camerounaises, sa mise en œuvre reste confrontée à une faible appropriation communautaire, à des résistances sociales et à un manque de communication adaptée.
L’objectif du travail est de concevoir une stratégie de communication sociale et comportementale visant à renforcer l’adhésion des communautés à cette intervention. Le mémoire s’appuie sur une analyse situationnelle approfondie, intégrant des données épidémiologiques, socioculturelles et communicationnelles. Il propose ensuite une campagne ciblée, articulée autour de messages clairs, de canaux adaptés (radios communautaires, agents de santé, leaders locaux) et de supports visuels compréhensibles.
La campagne vise à sensibiliser les parents, en particulier les mères, sur les avantages de la CPS, à corriger les fausses croyances, à encourager l’observance du traitement, et à renforcer la confiance envers les agents communautaires. Le document inclut un plan opérationnel, des outils de suivi-évaluation et une stratégie de pérennisation.
En conclusion, le mémoire souligne l’importance d’une communication contextualisée et participative pour améliorer la couverture et l’efficacité de la chimio-prévention du paludisme chez les enfants au Cameroun.
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
A Global Inventory of Alternative Medical Waste Treatment Technologies
La atención concedida a la equidad en la Agenda 2030 para el Desarrollo Sostenible obliga a encontrar nuevas formas de ampliar progresivamente los servicios a las poblaciones que no los reciben. Las alianzas satisfactorias entre el sector encargado del suministro de agua, el saneamiento y la higien...e (WASH, por su sigla en inglés) y los programas de lucha contra las enfermedades tropicales desatendidas (ETD) pueden contribuir a lograr esta aspiración. Sin embargo, colaborar para encontrar juntos esas nuevas formas, exige nuevos modos de pensar. En esta edición corregida se presenta un conjunto de herramientas para ayudar a los países y los programas de lucha contra la ETD a colaborar con la comunidad relacionada con las acciones de agua, saneamiento e higiene, y guía en la creación de alianzas, en la movilización de recursos y en el diseño, la aplicación y la evaluación de las intervenciones. Más que una guía de “buenas prácticas”, se trata de un conjunto de herramientas basadas en la experiencia adquirida en la realidad de un programa.
more
Over the past few decades and throughout the world, the landscape of adolescent health has been altered dramatically. Currently, the total population of adolescents between the ages of 10 and 19 years is 1.2 billion – the largest generation of young people in history. The vast majority of adolesce...nts (85%) live in developing countries where, in many areas, they make up more than a third of the population. They face a variety of different experiences given the diverse political, economic, social and cultural realities within their communities. Although, for many, adolescence is a period of learning and building confidence in a nurturing environment, for others it is a period of heightened risk and complex challenges.
more
Adolescence is a critical stage in life for physical, cognitive and emotional development, shaping future health and well-being. Comprehensive measurement of adolescent health is essential to prioritize health issues, guide interventions and track progress. However, global, regional and national ado...lescent health measurement has historically been inconsistent and incomplete.
more
The integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD)
La concentration en éthanol est mesurée par une méthode densitométrique à l’aide d’un alcoomètre Gay LUSSAC à l’échelle v/v.